Adlai Nortye Receives NMPA Approval for Pelareorep (AN1004) in China to Initiate Phase III Clinical Trials

HANGZHOU, China, March 21, 2019 /PRNewswire/ — Adlai Nortye Ltd. (“Adlai Nortye”), a global clinical-stage biopharmaceutical company today announced that it has received a clearance from the National Medical Products Administration (NMPA) of China for initiating the open-label, randomized, multicenter, global phase III clinical trial for pelareorep (AN1004) in combination with paclitaxel in patients with advanced/ metastatic breast cancer in China. Pelareorep is a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. In the presentation of pelareorep clinical data, additional randomized phase II data in metastatic breast cancer demonstrates doubling (21.8 months vs. 10.8 months) ...

Gepostet in der Kategorie Wirtschaft (Anzahl der ansichten:) 5

Ähnlich Nachrichten